Nintedanib in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Related Experiment Video
Updated: Dec 9, 2025

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation
Published on: July 10, 2012
Wenjiao Tang1, Ting Yu2, Tian Dong1
1Department of Hematology, Sichuan University West China Hospital, Chengdu, China.
Abstract:
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (allo-HCT) usually confers poor prognosis and high mortality. Currently, therapeutic options are limited. Here we report an 18-year-old man with acute myeloid leukemia developed BOS after allo-HCT and responded poorly to inhaled corticosteroids and short-acting β-agonist, azithromycin, montelukast, and immunosuppressants. Then he started nintedanib treatment, and the symptoms of nonproductive cough and dyspnea were alleviated gradually. His pulmonary function test revealed increased FEV1 compared to baseline.
More Related Videos
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
07:10Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
Published on: May 20, 2019
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...